Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | NPC1 | O15118 | 5/20 | 0.63 |
| ▸ | RAB9A | P51151 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | APAF1 | O14727 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | MGAM | O43451 | 1/20 | 0.57 |
| ▸ | SI | P14410 | 1/20 | 0.57 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354358 | 0.86 | SLC9A1 (0.65) | SLC9A1ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL3327335 | 0.86 | SLC9A1 (0.65) | SLC9A1ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL9476229 | 0.86 | SLC9A1 (0.65) | SLC9A1ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL1705814 | 0.83 | ALDH1A1 (0.62) | SLC9A1ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL3400235 | 0.83 | ALDH1A1 (0.59) | SLC9A1ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL19929559 | 0.82 | SLC9A1 (0.61) | SLC9A1ALDH1A1NPC1RAB9AMAPT | |
| Nitrafudam SCHEMBL29385280 | 0.82 | SLC9A1 (0.67) | SLC9A1ALDH1A1NPC1RAB9AMAPT | |
| Nitrafudam SCHEMBL121333 | 0.81 | SLC9A1 (0.66) | SLC9A1ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL11487837 | 0.80 | NPC1 (0.60) | SLC9A1ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL19929557 | 0.80 | MAPT (0.64) | SLC9A1ALDH1A1NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103768044-A | Application of active compounds for inhibiting dimerization of DJ-1 | UNIV ZHEJIANG | 2014-05-07 | — | — | CN | claimed |
| US-8586746-B2 | Amino-aza-adamantane derivatives and methods of use | ABBVIE INC. (US) | 2013-11-19 | — | — | US | claimed |
| EP-2476681-A2 | Amino-aza-adamantane derivatives and methods of use | Abbott Laboratories (US) | 2012-07-18 | — | — | EP | claimed |
| CN-101309922-A | Amino-aza-adamantane derivatives and methods of use | ABBOTT LAB (US) | 2008-11-19 | — | — | CN | claimed |
| EP-1926731-A2 | AMINO-AZA-ADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-04 | — | — | EP | claimed |
| WO-2007038058-A2 | AMINO-AZA-ADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-04-05 | — | — | WO | claimed |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | claimed |
| US-20040167204-A1 | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotien and metalloenzyme targets | FERNANDEZ-POL JOSE A (US) | 2004-08-26 | — | — | US | claimed |
| US-20030225155-A1 | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets | POL'S LABORATORIOS BIOTECHNOLOGY, S.A. (AR) | 2003-12-04 | — | — | US | claimed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-9919300-B2 | 1-hexene production process | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-03-20 | — | — | US | disclosed |
| EP-2484685-B1 | TRANSITION METAL COMPLEX, PREPARATION METHOD FOR SAID TRANSITION METAL COMPLEX, TRIMERIZATION CATALYST, PREPARATION METHOD FOR 1-HEXENE, PREPARATION METHOD FOR ETHYLENE POLYMER, SUBSTITUTED CYCLOPENTADIENE COMPOUND, AND PREPARATION METHOD FOR SAID SUBSTITUTED CYCLOPENTADIENE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-20020091135-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY GLOBAL INTELLECTUAL PROPERTY | 2002-07-11 | — | — | US | disclosed |
| US-20020042428-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
| WO-2002015662-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002017358-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002016355-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC) ACETYLCHOLINE RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167204-A1 | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotien and metalloenzyme targets | ZFX, ZFR, SLC30A6 | SLC9A1 3105/4885ALDH1A1 1453/4885NPC1 2838/4885 |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | CHRNA7, CHRNA5, CHRNA1 | SLC9A1 1073/4885ALDH1A1 1034/4885NPC1 1243/4885 |
| US-20020042428-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | NQO2, GBA1, UGT1A1 | SLC9A1 919/4885ALDH1A1 130/4885NPC1 33/4885 |
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PARK7, CYP3A7, UGT2B7 | SLC9A1 1115/4885ALDH1A1 267/4885NPC1 51/4885 |
| US-20030225155-A1 | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets | ZFX, ZFR, SLC30A6 | SLC9A1 2565/4885ALDH1A1 1314/4885NPC1 3159/4885 |
| US-20020091135-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | NQO2, GBA1, UGT1A1 | SLC9A1 919/4885ALDH1A1 130/4885NPC1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.